Extraintestinally invasive Escherichia coli (EC) that possess both a complete LPS and K1 capsule evade both complement-mediated bacteriolysis and neutrophil-mediated killing. Since C3H/HeJ mice that are hyporesponsive to LPS were uniquely susceptible to lethal infection with EC of this phenotype, we speculated there was an LPS-initiated host defense mechanism against this pathogenic phenotype. The LPS-normoresponsive C3H/HeN as well as the C3H/HeJ mice cleared these EC from the circulation within 4 h of intravenous administration. Whereas electron micrographs of the liver demonstrated these EC undergoing degeneration within the phagolysosomes of of both macrophages and Kupffer cells of C3H/HeN mice, these EC replicated within these cells of the C3H/HeJ mice. Restoration of anti-EC activity of C3H/HeJ mice occurred with activation of Kupffer cells and peritoneal macrophages in vivo with BCG and in vitro with IFN-y, but not with LPS. Pretreatment of C3H/ HeJ mice with a combination of recombinant murine IL-1 and TNF-a also restored the killing of K1 +-EC but did not enhance the killing of a K1--EC mutant. These data are consistent with the hypothesis that (a) there is no intrinsic inability of C3H/HeJ phagocytes to kill EC, but (b) an LPS-initiated, cytokine-mediated host defense mechanism is required for such killing. These studies emphasize the importance of bacterial surface characteristics in the interaction with specific host defenses. (J. Clin. Invest. 1995. 
Introduction
Successful pathogens with abilities to evade a variety of host defense mechanisms can invade host tissue, replicate, and disseminate from the site of initial invasion ( 1-3 ). Complement-mediated bacteriolysis is a highly efficient host defense mechanism that is effective against bacteria that lack an acid polysaccharide capsule (4) (5) (6) (7) and have a rough, part-rough, or incomplete, LPS phenotype (8) (9) (10) (11) . The clinical relevance of this mechanism was first demonstrated by Roantree and colleagues who reported that > 95% of strains retrieved from patients with bacteremia were able to resist the lethal effects of serum (12, 13) . This observation has been amply confirmed by other investigators (14) (15) (16) .
Neutrophil-mediated opsonophagocytic killing of bacteria is another defense mechanism by which invading bacteria are controlled by the host. In contrast to their ability to resist serummediated lysis, most bacteremic Escherichia coli are susceptible to opsonophagocytic killing. In a survey of over 200 consecutive bacteremic isolates of E. coli, most strains lacking a KI capsule, regardless of LPS phenotype, were easily killed by fresh, normal human serum in conjunction with normal human neutrophils (14) . Kl-encapsulated strains (and to a lesser extent K12-and K53-encapsulated strains), however, were poorly killed by this mechanism. Even among these opsonophagocytic resistant strains, those having a complete or smooth LPS phenotype were more resistant than those with a rough or part rough LPS phenotype.
These opsonophagocytosis-resistant, KI-encapsulated E. coli comprise > 20% of all bacteremic strains (14) (15) (16) (17) , yet the mortality in adults after infection with these strains is no greater than infection with non-Kl-encapsulated E. coli. This suggests that other defense mechanisms might be available to the host for overcoming infection with serum-resistant bacteria that are not susceptible to neutrophil-mediated killing.
We have previously shown that C3H/HeJ mice that are blocked in their ability to respond normally to LPS are highly susceptible to lethal infection after challenge with low levels of Ki-encapsulated bacteria possessing a smooth LPS phenotype (18) . The administration of the combination recombinant murine TNF-a and IL-a, however, protected these mice from > 10 LD50 bacterial challenge. In contrast, C3H/HeN mice whose responses to LPS were intact were significantly more resistant to lethal infection with the same organism. These data suggested that an LPS-mediated induction of a cytokine response might be an additional host defense mechanism against E. coli.
In the present study we show that such a cytokine-mediated defense mechanism might be a generalized, bacterial host response to bacteria that have both a smooth LPS phenotype and KI polysaccharide capsule, characteristics that permit the organism to evade serum bacteriolysis and neutrophil-mediated killing. Further, we show that such a cytokine-mediated defense mechanism optimally requires an activated macrophage and fresh normal serum. A practical implication of a beneficial, LPS-initiated host response is that modification of this mechanism (as might occur with treatment of patients with antibody to TNF or with IL-1 receptor antagonist, or after the induction of tolerance to LPS) might increase morbidity and mortality in those patients with bacteremia, but who are not in shock and who require an intact host defense mechanism to overcome the bacterial infection. Definition of LPS phenotypes. The LPS phenotype, depicted schematically on bacilli by core (squares) and polysaccharide repeat units (circles), can be defined on the basis of its reaction to 0-specific antisera, susceptibility to lysis by rough-LPS specific bacteriophages (RSP) , and appearance on SDS-PAGE.
Methods
Bacteria E. coli 0.18:K1:H7, strain Bort (originally provided by Dr. George Siber, Dana-Farber Cancer Institute, Boston, MA), and a Kinegative mutant have been previously described (19) . Rough LPS, Kipositive mutants of the parental strain were derived by TnlO mutagenesis (20 Bacteriophages. Rough-LPS specific bacteriophages (C21, Ffm, BR60, BR2, 6SR) were originally obtained from Dr. Bruce Stocker (Stanford University, Stanford, CA) and used as previously described (19) . The rough or part-rough LPS phenotype was defined as the ability of any one of these bacteriophages to cause lysis of a lawn of bacterial cells. Part-rough LPS strains were typable by agglutination with 0 antisera and had a typical "ladder" appearance on SDS-PAGE (Fig.  1) . Kl-specific bacteriophages (A-E) were originally obtained from Dr. Bernard Rowe (Central Public Health Laboratory, London, United Kingdom) and used as previously described (19 (23) . Briefly, mice were euthanized with 2 mg intraperitoneal pentobarbital, and the livers were perfused through the inferior vena cava with 50 ml Ca2+ and Mg2+-free HBSS (GIBCO, Gaithersburg, MD), followed by 50 ml of type IV collagenase (0.2 mg/ ml, Sigma Chemical Co., St 
Results
We determined the LD50 of bacteremic E. coli strains of various phenotypes in LPS-hyporesponsive C3H/HeJ mice to insure that the increased susceptibility to lethal infection of these mice was not limited to one unusually virulent strain. As shown in (19) . Table I , expression of a virulence phenotype even varied among smooth Ki-positive isolates. Although highly virulent (strains 221, 888), they were not as virulent as E. coli 018:K1:H7, strain Bort which had been selected from a large collection of extraintestinally invasive clinical isolates based on its particular virulence in an animal model (25) .
Just as with part-rough or KI-negative isolates (Table I) Light and electron microscopy. Since strain Bort was cleared from the bloodstream of both C3H/HeJ and C3H/HeN mice, and was cultured from both liver homogenates and Kupffer cell preparations, we next determined whether there were any morphologic correlates within the Kupffer cell which would predict the resurgence of E. coli, strain Bort, in C3H/HeJ mice after their initial clearance. Mice were challenged with bacteria intraperitoneally and their liver sections were examined at 48 h using light and electron microscopy. With light microscopic examination, the livers of both strains of mice inoculated with E. coli, strain Bort showed normal hepatocytes. No inflammatory cells were seen either in portal areas or lobules. No bacteria were seen in the livers of C3H/HeN mice. In contrast, the livers of C3H/HeJ mice were remarkable for the presence of enlarged Kupffer cells that contained numerous phagocytized E. coli in the cytoplasm (Fig. 3) .
Electron microscopic examination of the livers of C3H/HeJ mice revealed E. coli within expanded lysosomes of Kupffer cells (Fig. 4) . In some cells, bacteria were undergoing division (Fig. 4 B) . After 48 h, Kupffer cells were packed with E. coli and sometimes contained 50-100 bacteria (Fig. 5) . Replication of E. coli was so extensive that many liver cells were destroyed. E. coli were also seen in circulating monocytes (Fig. 6) , although in smaller numbers (not exceeding 10 organisms per section of the cell) than in Kupffer cells.
In contrast to the observations with C3H/HeJ mice, examination of liver by light microscopy at any time after inoculation of C3H/HeN mice did not reveal any bacteria. With electron microscopic examination, only single bacteria with atypical morphology reflecting bacterial degeneration were found in occasional Kupffer cells (Fig. 7, A and B) .
In vitro opsonophagocytic studies. The electron microscopic studies suggested that smooth LPS, KI-encapsulated phenotype E. coli were taken up by phagocytes of the C3H/HeJ mice. These mice, whose LPS-mediated responses were blocked, appeared unable either to kill the ingested bacteria or to prevent their active replication within phagolysosomes. These morphologic characteristics of the Kupffer cells of the C3H/HeJ mice, with bacteria replicating within the phagolysosome in contrast to the apparent destruction of these same bacteria within the phagolysosome of C3H/HeN mice, reflect the behavior of intracellular parasites within phagocytes that required further activation for intracellular killing (28) . To study whether the activation of phagocytes was required to limit the infection, we next compared the ability of both Kupffer cells and peritoneal macrophages from the C3H/HeJ and C3H,/HeN mice to kill E. coli, strain Bort, in an in vitro system. Neither strain Bort nor the Kl-negative mutant were killed by serum alone.
Kupffer cells from both strains of mice that were preincubated in medium alone for 48 h were found to kill poorly after an additional 3-h incubation period with the bacteria (no reduction in the original bacterial dose [1.08 X 105 CFU/ml] for the C3H/HeN cells and a reduction from 8 .0 x 104 to 6.6 X 104 CFU/ml [0.08 log] for C3H/HeJ cells, data not shown). Similarly, freshly isolated Kupffer cells from both C3H/HeJ and C3H/HeN mice were unable to kill bacteria in the absence of activation (data not shown). The addition of 50 U/ml IFNy, a known activator of macrophages (28) , during the preincubation period, however, resulted in a significantly increased killing of the challenge dose with both C3H/HeN and C3H/ HeJ cells (to 400 and 600 CFU/ml, respectively, a > 2 log reduction).
When interferon-activated peritoneal macrophages from both strains of mice were used in place of Kupffer cells, a reduction in bacterial challenge dose was also observed (.- 1.5 log reduction for both strains of mice respectively, Table II , experiment 1) similar to that observed with Kupffer cells. This macrophage-mediated bacterial killing required the presence of normal human serum. Since little bacterial killing was observed in the absence of interferon treatment, any activation of peritoneal macrophages during their elicitation by proteose-peptone irritation was apparently not sufficient by itself to activate the cells. As was true for Kupffer cells, no bacterial killing was observed when freshly isolated peritoneal macrophages were used (data not shown). In view of the similarity in the ability of Kupffer cells and elicited peritoneal macrophages to mediate the killing of the bacteria, we performed subsequent studies with the peritoneal macrophages.
Since the morphologic characteristics of E. coli within the Kupffer cells suggested the need for activation, and the initial in vitro experiments were consistent with this hypothesis, we examined further the requirements for the killing of these bacteria by activated phagocytes, by focussing on the ability of another known activator of macrophages, LPS, to prime the macrophages of C3H/HeJ and C3H/HeN mice. While IFN-,y and LPS were both able to activate the peritoneal macrophages of C3H/HeN cells for bactericidal kill (each > 2 log reduction), only the interferon was able to induce much bacterial kill by C3H/HeJ macrophages (2.3 log reduction for interferon vs 0.66 log for LPS activation, Table II, experiment 2) . Thus, the sus- ceptibility of C3H/HeJ mice to lethal infection by bacteria of a specific phenotype is not due to an intrinsic defect of the either the Kupffer cell or peritoneal macrophage phagocytes to be activated to kill these bacteria, but more likely reflects the inability of the C3H/HeJ phagocyte to be activated through an LPS-mediated pathway (or by another agonist that shared that pathway).
In addition to IFN--y, other cytokines are also able to prime the peritoneal macrophages of C3H/HeJ mice for bacterial killing (Table m) . M-CSF, IL-1, and TNF each activated these peritoneal macrophages in a dose-dependent manner. As might be anticipated from the protective effects of this cytokine combination in vivo (18) , combinations of IL-I and TNF have synergistic effects when used at concentrations that were ineffective when used alone.
Since C3H/HeJ mice that were pretreated with cytokines in vivo were able to resist lethal bacterial infection, and since phagocytes from these mice that were stimulated with IFN-y, IL-1, TNF, and M-CSF were able to efficiently kill these bacteria in vitro, we next assessed whether activation of C3H/HeJ phagocytes in vivo would similarly affect mortality. After pretreatment of mice with BCG, a known activator of macrophages (29), mice were able to withstand 10 times the challenge inoculum that caused 100% mortality in non-BCG-treated mice (Table IV). Thus, C3H/HeJ phagocytes that were activated in vitro with IFN-y, M-CSF, IL-1, and TNF or in vivo with BCG were capable of killing E. coli 018:K1:H7, strain Bort. C3H/HeN mice given a challenge of 3,240 CFU Bort cells (severalfold below its LDsO [18] ) in the absence of any pretreatment with BCG all survived (data not shown).
In an earlier study, we had demonstrated that pre-treatment of C3H/HeJ mice with a combination of recombinant murine IL-la and TNF afforded significant protection from lethal sepsis (18) . Consequently, when we showed in this study that the in vitro killing of E. coli 018:K1 strain Bort by cytokine-activated mononuclear cells required fresh normal serum, we decided to determine if the in vivo protection afforded by cytokine pretreatment also required an intact complement system. Mice pretreated with the combination of cytokines had increased survival from lethal bacterial challenge (9/13 survived in the cytokine group vs 1/13 without cytokine treatment, P = 0.004, two-tailed Fisher exact test); however, those mice pretreated with CVF to deplete complement before cytokine treatment were unable to resist lethal infection (2/14 survived in the CVF and cytokine treatment group vs 9/13 survivors in the cytokinetreated group that did not receive CVF, P = 0.006, two-tailed Fisher exact test). CVF treatment alone did not induce death in these mice. Thus, as was true for the in vitro killing of E. coli, enhancement of host defenses by the cytokines IL-1 and TNF could not confer increased protection in the absence of an intact complement system. Flow cytometry studies. Previous studies have demonstrated that the ability of monocyte-derived macrophages to phagocytize Mycobacterium leprae involves the expression of CR4, a maturation-dependent cell surface marker (CD1 lc/CD18; p150.95) that is minimally expressed on monocytes (30) . In our Kupffer cell preparation > 90% of freshly isolated cells from both C3H/HeN and C3H/HeJ mice expressed CR4 with mean channel fluorescence (MCF) of 206 and 129 respectively (Fig. 8) . Upon incubation of cells from both strains of mice in vitro, however, there was a decreased expression of CR4 in the absence of LPS or IFN--y after 48 h. Addition of interferon to the incubation media resulted in a nearly one log increase in percentage of CR4-expressing cells in C3H/HeJ cells (Fig. 8  D) , but a decrease in MCF (from 129 to 87). In contrast, incubation of C3H/HeN Kupffer cells with interferon was associated with a decrease in CR4 expression (both in terms of MCF and percentage of population expressing CR4; Fig. 8 C) (Table V) . With in vitro bactericidal assays, the Kinegative mutant of strain Bort was serum resistant, but, unlike the parental strain, was highly susceptible to killing mediated by neutrophils in the presence of fresh serum (26) . In contrast, Figure 6 . Electron micrograph of a circulating monocyte in a J ;small vessel of the liver of a C3H/HeJ mouse after the intraperitoneal inoculation with -100 CFU E. cli. containing 'oli in the phagosomes (arrows) and lysosome (double arrow). X23,000. the peritoneal macrophage-mediated killing of this mutant required the phagocyte to be activated in a manner similar to that needed for killing of the parental Bort strain. In the absence of treatment with interferon, there was no killing of the Kl-negative mutant (66,000 CFU/ml at 0 time to 70,000 CFU/ml at 3 h). However, when peritoneal macrophages were stimulated with r muIFN-y (50 U/ml) for 48 h, the bacterial inoculum was reduced to 900 CFU/ml in 3 h, a 99% reduction. Thus, CO2 in the presence of media alone, r muIFN-y (IFN, 50 U/ml), or lipopolysaccharide (LPS, 10 sg/ml). After extensive washing, bacteria were added in the presence or absence of fresh normal human serum (NHS). The number of bacterial CFU per well were determined at 0 time and 3 h. Data are from a single representative experiment with each variable run in triplicate. * Percentage of 0 time bacterial inoculum killed given in parentheses.
this KI capsule-negative E. coli phenotype appears to be adequately handled by host defense mechanisms different from those which handle the K1 capsule-positive parent.
Discussion
Our studies demonstrate that a clinically relevant isolate of E. coli with a phenotype that enables it to evade both serummediated bacteriolysis and neutrophil-mediated killing can be eliminated by a LPS-initiated host defense mechanism. We had earlier shown that C3H/HeJ mice are 10,000 times (Figs. 4-6 ) revealed the presence of this Kl-encapsulated E. coli within macrophages of C3H/HeJ mice, similar to what one would expect to observe in a macrophage that had not been activated. In contrast, the bacteria within the C3H/HeN macrophages were undergoing lysis (Fig.  7) , similar to what one would expect of a bactericidal event within an activated macrophage. Taken together, these observations are consistent with the interpretation that macrophages of both C3H/HeJ and C3H/HeN mice are able to ingest E. coli, but that macrophages of C3H/HeJ mice are unable to kill these bacteria in vivo, unlike the case with C3H/HeN macrophages. Thus, while other agonists (such as BCG or IFN-y) were capable of activating C3H/HeJ cells both in vitro and in vivo to provide a level of protection similar to that observed in C3H/ HeN mice, this was not occurring during the course of infection in C3H/HeJ mice (as it was during infection in the C3H/HeN mice). To account for these differences, we considered that perhaps the phagocytes had to be activated specifically by a LPS signal transduction pathway, and that only this LPS-initiated transduction pathway, or an agonist that may share this pathway, appears to be relevant to infection with these organisms in vivo. In fact, the different response in CR4 expression after exposure of Kupffer cells and peritoneal macrophages to LPS and interferon is preliminary evidence that these two agonists activate the cells by distinct signal transduction pathways. Further, we have observed in our laboratory that LPS modulates the cytokine repertoire of these mice in a manner that differs from that observed following BCG infection.
The microbicidal activity of activated macrophages from both strains of mice also requires fresh normal serum for optimal activity in the "triggering" step of the assay. The identity of this heat-labile serum factor and its mechanism of action are not clear. Preliminary evidence in our laboratory suggests that were it complement, it may facilitate uptake of the bacteria by the macrophage into intracellular compartments where the concentration of an effector molecule, such as nitric oxide, is greatest. Although heat-inactivated FCS was routinely included in the preincubation culture medium for the 48-72 h, activation of C3H/HeN cells was also achieved by preincubating cells with LPS in the absence of any serum (data not shown). When fresh serum was omitted or heat-inactivated during the triggering step, however, no killing was observed.
The effector mechanism(s) by which LPS-mediated killing occurs is not clear but would appear to involve the generation of cytokines. The induction of cytokines by monocytes after exposure to LPS is amply documented (32, 33) , and the administration of recombinant cytokines in vivo or in vitro as in this study to C3H/HeJ mice in vivo or its cells in vitro restored the microbicidal activity. Although some cytokines, such as interleukin-l, have been reported to increase the uptake of E.
coli by phagocytes (34) , the electron micrographs and clearance studies indicate that strain Bort is taken up by mononuclear phagocytes of C3H/HeJ mice. Rather, the LPS-mediated pathway appears to be primarily involved in the killing step(s). TNF has been shown to be a potent inducer of oxidative microbicidal pathways (35, 36) . Preliminary evidence from our laboratory has shown that the bactericidal activity of activated C3H/HeJ macrophages may be mediated through a nitric oxide mechanism (37). Cytokines have been shown to have an important role in this effector pathway as well (38) .
These findings confirm and extend previous studies that show the efficacy of specific host defense mechanisms is highly dependent on the surface characteristics of the target bacteria (4-11, 14-16, 19, 20) . Bacteria that lack an acid polysaccharide capsule and complete LPS phenotype are easily killed by complement (5, 8) . Bacteria that have a complete LPS or capsular polysaccharide are more easily killed by neutrophils and serum. The presence of either specific capsular polysaccharides, such as the K1 polysaccharide, or smooth LPS permit the bacteria to evade this mechanism, however (14) . In this study we show that these latter bacteria can be killed by an additional host defense mechanism, but requires the generation of cytokines through an LPS-activated signal transduction pathway. Such a mechanism was not required for controlling infection by the Kl-negative, smooth LPS mutant of strain Bort (Table V) .
If LPS initiates important host defenses against invading pathogens by the induction of cytokine-mediated pathways, then its interruption by cytokine modulators (e.g., mAbs to the cytokines or cytokine receptor antagonists) could lead to accelerated infection and death upon exposure of the host to an invasive pathogen. Thus, in those patients (or animals) whose LPS-initiated pathways are under stress, but still intact, the administration of such modulators would be expected to produce detrimental results as observed both experimentally (39, 40) and in recent clinical trials with IL-1 receptor antagonist and anti-TNF mAb (41 ) where there was increased mortality in the treatment compared to the placebo group; however, in animals (40, 42, 43) and patients whose LPSinitiated pathways have already escaped regulatory control and in whom autocrine activation has led to excessive amounts of cytokine production, cytokine inhibitors could be beneficial by returning the biologic system towards equilibrium. This may allow host regulatory systems to reassert control and lead to improved outcome. This is also consistent with what was observed in these clinical trials where patients most ill (i.e., highest APACHE scores) appeared to benefit from cytokine modulation with IL-1 receptor antagonist and anti-TNF mAb. Under these conditions one would desire to administer only those amounts of cytokine modulator sufficient to restore balance, but not to completely interrupt these events. Thus a deleterious response to LPS, sepsis, may occupy one end of the same continuum occupied by a beneficial LPS-initiated pathway, such as the one described in the present studies.
In summary, we have described a mechanism by which the host can combat infection with E. coli and perhaps other bacteria previously thought to be handled primarily by the humoral immune system. This mechanism requires the activation of mononuclear phagocytes through an LPS signal transduction pathway, the generation of cytokines and the need for fresh serum during the triggering of the phagocytes upon encountering the bacteria. This pathway is utilized by the host in killing bacteria that have a smooth LPS phenotype and specific acid polysaccha-ride capsules that are most resistant to killing by previously described host defenses, but does not enhance activity against KI-negative strains that are efficiently handled by other host defense mechanisms. These studies emphasize the importance of bacterial surface characteristics in the interaction with specific host defense mechanisms, and also suggest a need to better define those infected patients who would benefit from anticytokine therapy.
